Elsevier

Clinical Therapeutics

Volume 27, Issue 8, August 2005, Pages 1215-1227
Clinical Therapeutics

An open-label, noncomparative study of miglustat in type I Gaucher disease: Efficacy and tolerability over 24 months of treatment*

https://doi.org/10.1016/j.clinthera.2005.08.004Get rights and content

Abstract

Background:

The substrate synthesis inhibitor miglustat (N-butyldeoxynojirimycin) is the first oral agent to receive regulatory approval for the treatment of type I Gaucher disease (GD).

Objectives:

The aims of this study were to further assess previous observations of the effects of miglustat in adult patients with mild to moderate type I GD and to evaluate the tolerability and safety profile of this drug.

Methods:

This was a noncomparative, open-label study in adult patients with type I GD (confirmed by genotyping and glucocerebrosidase assay) who were unwilling or unable to receive enzyme replacement therapy (ERT) or who had discontinued ERT for at least 3 months. Patients received miglustat 100 mg TID for 12 months, with the option of continuing treatment for a further 12 months. The primary end point was the percentage change in liver volume. Secondary end points included the percentage change in spleen volume and changes in hematologic parameters (hemoglobin, platelets), chitotriosidase activity (a surrogate marker of disease burden), and bone assessments (dual-energy X-ray absorptiometry, magnetic resonance imaging, and radiography). Clinical safety was monitored, including assessment of neurologic status at baseline and throughout the study using a comprehensive battery of standardized neurologic tests (eg, Purdue Pegboard Test, Mini-Mental State Examination, nerve conduction studies) and neuropsychological tests.

Results:

Of the 10 patients (7 men, 3 women) who received at least 1 dose of miglustat, 7 completed 24 months of treatment. Patients were aged between 32 and 62 years (mean, 46.3 years) and weighed between 55 and 88 kg (mean, 72.4 kg). All patients had at least 1 manifestation of GD, including 10 with splenomegaly (mean size, 8.1 times normal; range, 3.9–15.9 times normal), 9 with thrombocytopenia, and 8 with hepatomegaly (mean size, 1.5 times normal; range, 1.0–2.0 times normal). At baseline, hemoglobin concentrations ranged from 11.5 to 15.1 g/dL (mean, 13.2 g/dL), platelet counts from 55 to 161 × 109/L (mean, 83.8 × 109/L), and chitotriosidase activity from 526 to 29636 nmol/mL · h (mean, 8143.7 nmol/mL · h). In the 8 patients comprising the efficacy set, significant mean percentage changes from baseline in liver volume were seen at 6 months (−8.4%; P = 0.036; 95% CI, −16.1 to −0.7) and 18 months (−15.1%; P = 0.022; 95% CI, −27.1 to −3.0). Although not statistically significant, the 95% CIs for the percentage changes in liver volume at 12 months (−9.4%; 95% CI, −19.5 to 0.6) and 24 months (−5.6%; 95% CI, −12.1 to 1.0) were similar to those at 6 and 18 months, supporting a consistent clinical effect. Significant mean percentage reductions in spleen volume were observed at 6 months (−19.0%; P = 0.006; 95% CI, −30.4 to −7.6) and 18 months (−24.3%; P = 0.001; 95% CI, −33.6 to −15.1). Mean hemoglobin concentrations, which were normal at baseline, remained stable over the course of the study. There were no significant changes in bone status. There was a significant mean increase in absolute platelet count at 12 months (by 13.9 × 109/L; P = 0.030; 95% CI, 1.8 to 26.0); at 24 months, the mean percentage increase from baseline (23.0%) was not statistically significant. The mean percentage reduction from baseline in chitotriosidase activity at 24 months was 25.3%. Treatment was well tolerated, and the incidence of most adverse events decreased with time. Gastrointestinal and central nervous system adverse events reported during 3-month periods at the beginning (0–3 months) and end (>21–24 months) of the study were flatulence (10 and 2 patients, respectively), diarrhea (9 and 0), abdominal pain (7 and 1), tremor (4 and 1), paresthesia (3 and 0), headache (2 and 3), and abdominal distention (2 and 0). No evidence of clinically significant adverse effects on neurologic or neuropsychological function was found during the study.

Conclusions:

In this small study in symptomatic adult patients with type I GD, miglustat treatment resulted in a significant decrease in liver and spleen volume at 6 and 18 months, with clinical improvement noted over 24 months. Bone involvement and platelet and hemoglobin values remained stable, with no significant changes noted during the observation period. The effects of treatment were consistent with those of earlier studies of miglustat in type I GD.

References (45)

  • CoxT et al.

    Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis

    Lancet

    (2000)
  • TrouillasP et al.

    International Cooperative Ataxia Rating Scale for pharmacological assessment of the cerebellar syndrome

    J Neurol Sci

    (1997)
  • FolsteinMF et al.

    “Mini-mental state.” A practical method for grading the cognitive state of patients for the clinician

    J Psychiatr Res

    (1975)
  • ZimranA et al.

    Gaucher disease. Clinical, laboratory, radiologic, and genetic features of 53 patients

    Medicine (Baltimore)

    (1992)
  • KnudsonAG et al.

    Genetics of the sphingolipidoses

  • LachmannRH et al.

    Twin pairs showing discordance of phenotype in adult Gaucher's disease

    QJM

    (2004)
  • BartonNW et al.

    Replacement therapy for inherited enzyme deficiency—macrophagetargeted glucocerebrosidase for Gaucher's disease

    N Engl J Med

    (1991)
  • GrabowskiGA et al.

    Enzyme therapy in type 1 Gaucher disease: Comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources

    Ann Intern Med

    (1995)
  • CampbellPE et al.

    A model of neuronopathic Gaucher disease

    J Inherit Metab Dis

    (2003)
  • CoxTM et al.

    The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: A position statement

    J Inherit Metab Dis

    (2003)
  • VunnamRR et al.

    Analogs of ceramide that inhibit glucocerebroside synthetase in mouse brain

    Chem Phys Lipids

    (1980)
  • PastoresGM et al.

    A neurological symptom survey of patients with type I Gaucher disease

    J Inherit Metab Dis

    (2003)
  • Cited by (121)

    • Developmental and Inherited Liver Disease

      2023, MacSween's Pathology of the Liver, Eighth Edition
    • Bone marrow burden score is not useful as a follow-up parameter in stable patients with type 1 Gaucher disease after 5 years of treatment

      2021, Blood Cells, Molecules, and Diseases
      Citation Excerpt :

      Nonetheless, we must highlight that none of the patients who were on SRT experienced any significant reduction in BMB during the first 24 months of treatment. This is consistent with the findings of Pastores et al. [28], who followed 10 patients on miglustat for 24 months and observed no changes in BMB score after treatment. Chitotriosidase activity correlated positively with BMB throughout the study period.

    • Rare GBA1 genotype associated with severe bone disease in Gaucher disease type 1

      2019, Molecular Genetics and Metabolism Reports
      Citation Excerpt :

      Also, the pattern of decrease of the BMB score during treatment shows that patient 1, who was being treated with ERT for 24 months, presented a fast response with a significantly drop in the total score when compared to patient 2, who was beign treated with SRT for 24 months and only 1 month with ERT. This is in accordance with previous studies that have shown that BMB tend to decrease during the first years of ERT, but this cannot be observed with SRT, and, also, the response is not known to reflect disease severity [22,23]. At admission, neither patient was profoundly thrombocytopenic nor anemic.

    View all citing articles on Scopus
    *

    This work was presented as an abstract at the 54th Annual Meeting of the American Society of Human Genetics, October 26–30, 2004, Toronto, Canada.

    View full text